Document:

EX-10.40

 Exhibit 10.40 

Amendment 
 to the Employment
Agreement dated December 21st, 2011 
 by and between 

Teva Pharmaceuticals Europe B.V. and Rob Koremans 

This Amendment (this “Amendment”) is made this 30th day of October, 2012, by and among Teva Pharmaceuticals Europe B.V. (the
“Company”) and Rob Koremans (the “Employee”) to the Employment Agreement entered into between the Company and Executive dated December 21st, 2011 (the
“Agreement”). 
 Whereas, the Company and Employee have entered into the Agreement; and 

Whereas, the Parties wish to amend certain terms of the Agreement as set forth below. 

Now therefore, in consideration of the mutual covenants herein contained, the parties hereto agree as follows: 

 

	 	1.	Except as expressly set-forth in this Amendment, all terms and conditions of the Agreement shall continue in full force and effect. 

 

	 	2.	A new Section 5A shall be inserted into the Agreement immediately following Section 5 and shall provide as follows: 

“Change of Control 

If the Employee’s employment is terminated by the Company without cause within one (1) year following a merger of the Company with
another entity, pursuant to which merger the Company is not the surviving entity, and such termination is as a result of such merger, the Company shall pay the Employee an additional severance payment [in addition to any severance amounts to which
the Employee is entitled pursuant to the terms of this Agreement] in an amount equal to one and one-half million dollars ($1,500,000) (the “Change of Control Severance Payment”). The Change of
Control Severance Payment shall be paid to the Executive in Euros calculated according to the Euro-US Dollar rate of exchange last published by the European Central Bank, in a lump sum on the next regular
payroll date immediately following the sixtieth (60th) day after the date of termination. 
 For the purposes of this Section 5A, the
term “Company” shall refer only to the Company’s parent, Teva Pharmaceutical Industries Ltd.” 
  

	 	3.	This Amendment may be executed in multiple counterparts, each of which will be deemed to be an original and all of which will be deemed to be a single agreement. 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written
above. 
  

			
	                                      
                              	  	/s/ Rob Koremans                
	Teva Pharmaceuticals Europe B.V.	  	Rob Koremans

  
 2EX-10.41

 Exhibit 10.41 

SECOND AMENDMENT 
 This
Second Amendment (the “Second Amendment”) dated as of January 12, 2015, is entered into by and among Teva Pharmaceuticals Europe B.V. (the “Company”) and Rob Koremans (the “Employee”). 

WHEREAS, the Company and the Employee entered into an Employment Agreement dated December
1st 2011 and amended on October 30th 2012 (the “Agreement”), providing for the Employee’s employment by the Company, and
setting forth the terms and conditions for such employment; and 
 WHEREAS, the Company and the Employee desire to amend the Agreement as
set forth below. 
 NOW, THEREFORE, on the basis of the foregoing premises and in consideration of the mutual covenants and agreements
contained herein, the parties hereto agree as follows: 
  

	 	1.	Section 4.2 shall be deleted in its entirety and replaced with the following: 

 “For
each fiscal year that ends during the term of Employment, the Employee shall be eligible to participate in the Company’s annual cash bonus plan in accordance with Teva pharmaceutical Industries, Ltd. (“TPI”) Compensation Policy
(the “Annual Bonus”). The Annual Bonus shall be paid to the Employee at the same time as annual bonuses are generally payable to other similarly situated senior executives of TPI subject to the Employee’s continuous
employment through the payment date except as otherwise set forth in this Agreement.” 
  

	 	2.	Section 6.2 shall be deleted in its entirety and replaced with the following: 

“During the period from the date of execution of this Second Amendment up to March
31st 2018, and subject to continuation of the Employment during that period, the Company shall provide Employee with the right of use a Company-leased apartment in Amsterdam for which the lease
costs for the Company (inclusive of all variables costs, e.g., utilities, service costs, parking costs, insurance, taxes and VAT) will not exceed EUR 4,200 per month. Any excess (lease) costs associated with the apartment will be for Employee’s
account and may be set-off by the Company against any monies owed to Employee.” 
  

	 	3.	The maximum amount of car allowance specified in Section 4.5 shall be revised, effective July 1, 2012, from EUR 24,000 to EUR 33,600. 

	 	4.	Words and phrases defined in the Agreement shall bear the same meaning where used in this Second Amendment. 

  

	 	5.	The Agreement shall be construed in conjunction with this Second Amendment as an integral part thereof and shall remain of full force and effect, save as specifically amended in this Second Amendment. 

 

	 	6.	This Second Amendment may be executed in multiple counterparts, each of which shall be deemed an original and all of which together shall be considered one and the same agreement. 

IN WITNESS whereof the parties hereto have executed this Agreement on the day and year first written above. 

 

			
	  
	  	 /s/ Rob Koremans

	Teva Pharmaceuticals Europe B.V.	  	Rob Koremans
	Represented by Teva Pharmaceutical Industries, Ltd. as its sole shareholderEX-10.42

 Exhibit 10.42 

EXECUTION VERSION 
 THIRD
AMENDMENT 
 This third Amendment (the “Third Amendment”) is made on September 18, 2017, is entered into by and among Teva
Pharmaceuticals Europe B.V. (the “Company”) and Rob Koremans (the “Employee”). 
 WHEREAS, the Company and the Employee
entered into an Employment Agreement, the terms and conditions whereof have been recorded inter alia in an employment contract dated December 21st, 2011 (the “Contract”) as amended on October 30, 2012 and January 12, 2015
(the “Agreement”), providing for the Employee’s employment by the Company, and setting forth the terms and conditions for such employment; and 

WHEREAS, the Company and the Employee desire to amend the Agreement as set forth below. 

NOW, THEREFORE, on the basis of the foregoing premises and in consideration of the mutual covenants and agreements contained herein, the
parties hereto agree as follows: 
  

	 	1.	The following paragraph shall be added immediately at the end of Section 5 of the Contract: 

“In addition, in case of termination by the Company (other than for an urgent cause within the meaning of Dutch law) and subject to
Employee achieving certain goals that will be agreed between the Employee and the CEO and execution of a non-revocable waiver and release of claims against the Company and any member of the Company’s
group, any equity awards that were and/or will be granted to Employee until the formal date of termination of the Contract shall continue to vest for the Extended Period as if Employee had remained employed by the Company, in accordance with the
terms and conditions of TPI’s equity plans and the individual award agreements evidencing such grants (including, for the avoidance of doubt, any performance vesting conditions) and the vested portion of any options as of the end of the
Extended Period shall continue to be exercisable through their stated expiration date, following which any portion of such options not exercised will expire (the “Continued Vesting Benefits”). 

For the purpose of this Section 5, the Extended Period shall mean the later of (i) a period of fourteen months (14) from the
formal date of termination of the Contract , or (ii) March 1, 2020.                 

	 	2.	The following section 5.1 shall be added immediately following Section 5A of the Contract: 

“Notwithstanding anything to the contrary in Section 1.4 and Section 5, in the event (i) notice of
termination of employment is served by Employee on or after July 1st, 2018, and (ii) subject to achieving certain goals that will be agreed between the Employee and the CEO; and (iii)
Company and Employee mutually agreeing on the exact date of the termination of the employment, then Employee shall be entitled to the same treatment as if he was terminated by the Company other than for an urgent cause within the meaning of Dutch
law. For the avoidance on doubt, this Section 5.1 shall not apply to Change of Control Severance Payment.     
  

	 	3.	Words and phrases defined in the Agreement shall bear the same meaning where used in this Third Amendment. 

  

	 	4.	The Agreement shall be construed in conjunction with this Third Amendment as an integral part thereof and shall remain of full force and effect, save as specifically amended in this Third Amendment. 

 

	 	5.	This Third Amendment may be executed in multiple counterparts, each of which shall be deemed an original and all of which together shall be considered one and the same agreement. 

– Signature page follows – 

  
 2 

 IN WITNESS whereof the parties hereto have executed this Agreement on the day and year first written above. 

 

			
	  
	  	 /s/ Rob Koremans

	 Teva Pharmaceuticals Europe B.V.
  

 
	  	Rob Koremans
	Teva Pharmaceuticals Europe B.V.EX-10.43

 Exhibit 10.43 

EXECUTION VERSION 
 TERMINATION AGREEMENT

 (beëindigingsovereenkomst) 
  

	1.	TEVA PHARMACEUTICALS EUROPE B.V., a limited liability company according to the laws of the Netherlands, registered in the Dutch trade register under number 30110625 (“TPE”);

 and 
  

	2.	Mr ROBERT KOREMANS , born on 27 July 1962, residing at Valeriusplein 14f, 1075 BH Amsterdam, The Netherlands (“Employee”); 

hereafter jointly: the “Parties”; 

WHEREAS: 
  

	a.	Employee has been employed by TPE as from 1 March 2012, currently on the basis of an indefinite term employment agreement governed by Dutch law (the “Employment Agreement”). Employee currently
fulfils the position of President & CEO Global Speciality Medicines of the Teva Group (defined as Teva Pharmaceutical Industries and its direct and indirect subsidiaries) and Employee has been appointed as board member (bestuurder)
of TPE as per 1 March 2012, which appointment has been accepted by Employee; 

  

	b.	The terms and conditions of the Employment Agreement have been laid down in an employment contract executed by Employee on 21 December 2011 (the “Employment Contract”), as amended in three
subsequent Addenda/Amendments and supplemented by an Indemnification and Release Agreement (the “Addenda”); 

  

	c.	The parties agree that the Employment Agreement should be terminated, without there being any urgent cause within the meaning of article 7:677/678 Dutch Civil Code; 

 

	d.	In this agreement (the “Agreement”), Parties wish to formalise the termination of the Employment Agreement and wish to arrange the effects of the termination of the Employment Agreement between
them and the matters that will arise as a consequence thereof; 

	e.	The date written at the top of this instrument will be referred to as the “Execution Date” in this Agreement; 

HAVE AGREED AS FOLLOWS: 
 Termination/ resignation
from board position 
  

	1.	TPE and Employee hereby terminate the Employment Agreement with mutual consent effective on 31 May 2018 (the “Termination Date”). 

 

	2.	Employee hereby resigns as board member (bestuurder) or officer of any and all Group Companies, including TPE, effective as per 27 November 2017 or the earliest possible date thereafter, to the extent
Employee has been appointed board member or officer of such Group Company. At the request of any such Group Company or its shareholders, Employee will execute each and every instrument considered necessary to effectuate such resignation under the
laws governing such Group Company. This provision will be considered to create third party rights for the benefit of (the shareholders of) such Group Companies. 

The Employment Agreement will, notwithstanding the above resignation as board member of TPE, continue up to the Termination Date. 

Severance & other entitlements 
  

	3.	Employee shall be entitled to such severance and other emoluments as prescribed in the Employment Contract and the Addenda, which entitlements shall be considered to be in full satisfaction of all statutory entitlements
and (other) claims Employee may have pursuant to the Employment Agreement, to the extent no specific arrangements on such claims have been reflected in this Agreement. 

Release from duties 
  

	4.	 As from the Execution Date, Employee will step down and be released from any duties relating to the position of
Head of GSM and any other position he holds, and –as from that date and up to and 

  
 2 

	 	including 31 December 2017- Employee shall assist in transitional activities as requested by and in accordance with any specific directions given by Teva Pharmaceutical Industries, Ltd., and/or TPE and/or a Group
Company. 

  

	5.	As from 31 December 2017 and up to and including the Termination Date (the “Release Period”), Employee shall be required to respond to inquiries and assist as may be reasonably requested by the
Company and/or a member of the Company Group. 

 Final settlement of accounts 

 

	6.	As per the Termination Date, a final settlement of accounts (eindafrekening) will be made, taking into account the provisions of this Agreement (excluding the Severance) and all other written agreements between
Parties and the relevant provisions of Dutch law (the “Final Settlement of Accounts”). 

  

	7.	Employee acknowledges that there are no oral arrangements regarding employment conditions between Employee and TPE, which deviate from the employment conditions as laid down in written agreements, signed by both
Parties. In the event of contradiction between such other written agreements and this Agreement, the provisions of this Agreement shall prevail. 

  

	8.	Notwithstanding any deviating provisions in this Agreement or in the Employment Contract and Addenda, Employee will remain entitled to full payment of salary and other benefits under the Employment Agreement up to and
including the Termination Date. 

  

	9.	Employee acknowledges that a decision was made not to pay annual bonus to (inter alia) any Group Executive Officers, including Employee, for the year 2017 and agrees to be bound by such decision. In
addition,    Employee shall not be entitled to participate in the 2018 Bonus Scheme and shall not be entitled to be considered for equity awards or other long-term incentives. 

 

	10.	Employee shall be entitled to (pro rata) holiday allowance up to and including the Termination Date, to the extent not included in the (base) salary. To the extent payable and not paid already, the holiday allowance
shall be paid out under the Final Settlement of Accounts. To the extent an overpayment of holiday allowance has been made to Employee, such overpayment shall be included in the Final Settlement of Accounts as a deductible. 

  
 3 

 Miscellaneous 
  

	11.	Employee will cooperate with any internal and/or external investigation(s), proceedings or inquires, being in progress on the Execution Date or initiated later within the Group, as to be requested by the Group or any
outside legal counsel and/or other professional advisors engaged by the Group for that purpose. Employee will in that respect, inter alia, provide all requested information and participate in internal hearings. Employee shall consider, in good
faith, requests from competent regulating/governing bodies to cooperate in ongoing or new governmental investigations with respect to activities of the Group, in such form and to the extent as may be required for the purposes of such investigations,
and during the entire period of their duration. 

  

	12.	Any post termination provisions in Employee’s Employment Agreement, including without limitation those on competition, non-solicitation confidentiality and/or IP, as well as
any penalty clauses relating thereto and the Indemnification and Release Agreement dated September 12, 2012, will remain in force. 

  

	13.	Employee shall not make any disparaging or defamatory comments regarding any member of the Group or any of its current or former directors, officers, employees or products. 

 

	14.	Provided that the provisions of this Agreement will have been fulfilled, Employee hereby in advance grants TPE and all Group Companies full and final discharge in respect of, and explicitly waives, any and all (further)
claims, rights and/or entitlements Employee has or (may) have that may arise from his employment with TPE and/or pursuant to the Employment Agreement and/or the termination thereof. 

 

	15.	The Parties consider this Agreement to be a settlement agreement (vaststellingsovereenkomst) within the meaning of article 7:900 Dutch Civil Code. 

 

	16.	The Parties hereby waive their respective rights to rescind this Agreement or have this Agreement rescinded, irrespective of the nature of the breach of contract (tekortkoming in de nakoming). 

  
 4 

	17.	This Agreement is construed in accordance with and shall be governed by the laws of the Netherlands. 

 IN
WITNESS whereof Parties have executed this Agreement in two original copies on the date written at the top of this instrument 
 Teva Pharmaceuticals Europe
B.V. 
  

			
	                                     
                                   	  	/s/ Robert
Koremans                                        

	 By:
                        
  
	  	 Robert Koremans
  

	 Title: board member
  
	  	Date:
	Date:	  	

  

			
	/s/ David
Vrhovec                                        
    	 	
	 By: David Vrhovec
  
	 	
	Title: board member	 	
	  
 Date:
	 	

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]